15
Participants
Start Date
August 14, 2024
Primary Completion Date
April 30, 2027
Study Completion Date
April 30, 2027
Taxotere
75 mg/m2 once every 21 days for 4 cycles
Cytoxan
600 mg/m2 once every 21 days for 4 cycles
Trastuzumab deruxtecan
5.4 mg/kg once every 21 days for 5 cycles
Sacituzumab govitecan
10 mg/kg on days 1 and 8 cycled every 21 days for 5 cycles
Xeloda
1000 mg/m2 orally twice daily for 14 days cycled every 21 days for 5 cycles
Fulvestrant
500 mg intramuscular (IM) on days 1, 15 and 28 of the first cycle followed by every 28 days for a total of 4 cycles
Ribociclib
600 mg orally daily 21 days on, 7 days off
Abemaciclib
150 mg by mouth twice daily
RECRUITING
Moffitt Cancer Center, Tampa
H. Lee Moffitt Cancer Center and Research Institute
OTHER